Bicycle Therapeutics (BCYC) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 17.0% versus a loss of 53.9%. Over five years, VNDA leads with a -75.4% price change compared with -93.6% for BCYC. Vanda Pharmaceuticals is the larger company by market cap ($275.4 million vs $271.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | VNDA |
|---|---|---|
| Share price | $3.88 | $4.56 |
| Market cap | $271.57M | $275.41M |
| 1-day change | +1.84% | +0.55% |
| YTD return | -46.19% | -48.64% |
| 1-year return | -53.87% | -17.03% |
| 5-year return | -93.57% | -75.39% |
| Forward P/E | — | 22.78 |
| EPS (TTM) | $-2.73 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $9.94 |
| 52-week low | $3.33 | $4.27 |
| Distance from 52-week high | -57.36% | -54.18% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +144.85% | +157.96% |
| Average volume | 387.29K | 974.13K |
| Shares outstanding | 50.55M | 60.46M |
| Employees | 288 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed BCYC by 36.8 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
BCYC vs VNDA FAQ
Which is bigger, Bicycle Therapeutics or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $275.41M compared with $271.57M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.